Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen
signaling. Androgen deprivation therapy and second-generation androgen receptor (AR) …

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with
diverse drivers of disease progression and mechanisms of therapeutic resistance. We …

PURPOSE Metastatic prostate cancer is initially sensitive to androgen receptor inhibition,
but eventually becomes castration-resistant prostate cancer (mCRPC). Early use of more …

Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer
(mCRPC), but there have been few whole-genome sequencing (WGS) studies of this …

Men with metastatic prostate cancer who are treated with androgen deprivation therapies
(ADT) usually relapse within 2 to 3 years with disease that is termed castration-resistant …

Background Androgen-deprivation therapy (ADT) is standard treatment for locally advanced
or metastatic prostate cancer (PCa). Many patients develop castration resistance (castration …

Progression of primary prostate cancer to castration-resistant prostate cancer (CRPC) is
associated with numerous genetic and epigenetic alterations that are thought to promote …

Metastatic prostate cancer is characterized by recurrent genomic copy number alterations
that are presumed to contribute to resistance to hormone therapy. We identified CHD1 loss …

Context Recent studies focused on the molecular characterization of metastatic prostate
cancer have identified genomic subsets and emerging resistance patterns. Detection of …

In castration-resistant prostate cancer (CRPC), the loss of androgen receptor (AR)
dependence leads to clinically aggressive tumors with few therapeutic options. We used …